Furthermore, we selected NGS-diagnosed BRAF or NRAS mutation positive cutaneous melanomas, BRAF mutation positive hairy cell leukemia, KRAS or EGFR mutation positive lung adenocarcinomas, and BRAF, KRAS or NRAS mutation positive colorectal cancer cases to assess what proportion of the identified mutations would have been recognized on the Idylla platform. This evidence concerns the gene BRAF and hairy cell leukemia.